Alzendi NA, Badawi AH, Alhazzaa B, Alshahrani A, Owaidhah O. Topiramate-induced angle closure glaucoma: Two unique case reports.
Saudi J Ophthalmol 2021;
34:202-204. [PMID:
34085015 PMCID:
PMC8081079 DOI:
10.4103/sjopt.sjopt_9_20]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2020] [Revised: 10/31/2020] [Accepted: 12/02/2020] [Indexed: 01/25/2023] Open
Abstract
The aim of this study is to report the side effects of oral topiramate in two young patients presented with bilateral ocular blurring and discomfort, causing unique development of secondary acute angle closure (AAC) after discontinuation of oral topiramate. Both patients, with a history of seizure and migraine, respectively, were taking oral topiramate to control their mentioned diseases. Both had secondary AAC and high intraocular pressure, after discontinuing topiramate. They were treated with topical medications and underwent initial and subsequent multimodal imaging to track up their response to the management. Ocular side effect, during topiramate use and possibly even after discontinuation, will improve early detection of secondary AAC. Topical management along with multimodal imaging of such cases can give optimal results.
Collapse